Verve Therapeutics, Inc. Quarterly Income Tax Expense (Benefit) in USD from Q2 2022 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Verve Therapeutics, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q2 2022 to Q2 2024.
  • Verve Therapeutics, Inc. Income Tax Expense (Benefit) for the quarter ending June 30, 2024 was $66K, a 62.5% decline year-over-year.
  • Verve Therapeutics, Inc. Income Tax Expense (Benefit) for the twelve months ending June 30, 2024 was $271K.
  • Verve Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2023 was $275K, a 419% increase from 2022.
  • Verve Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2022 was $53K.
  • Verve Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2021 was $0.000.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $271K $66K -$110K -62.5% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $381K $106K +$106K Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $275K $32K Oct 1, 2023 Dec 31, 2023 10-K 2024-02-27
Q3 2023 $67K +$67K Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-07
Q2 2023 $176K +$176K Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $0 Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q3 2022 $0 Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 $0 Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.